Pharmacogenomics Market Report 2026

Pharmacogenomics Market Overview

• Pharmacogenomics market size has reached to $9.84 billion in 2025 • Expected to grow to $15.98 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Proliferation Of Chronic Diseases Driving Growth In Pharmacogenomics Market Due To Personalized Medicine Advancements • Market Trend: Embedding AI-Powered Drug-Drug Interaction Management Through Deep Genomic Insight • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pharmacogenomics Market?

Pharmacogenomics is a field of research that studies how a patient's genes affect and how they respond to medications. The long-term aim of pharmacogenomics is to help doctors select the drugs and doses best suited for each person. Pharmacogenomics is used to create customized drugs to treat a variety of health issues, including cardiovascular disease, Alzheimer's disease, cancer, and asthma. The pharmacogenomics marker refers to precise medical treatment for each person or a group of people. The main technologies used in the pharmacogenomics market a next-generation sequencing (NGS), polymerase chain reaction, gel electrophoresis, mass spectrometry, microarray, and other technologies. NGS is a massively parallel sequencing technology that provides ultra-high throughput, scalability, and speed. The technology is used to determine the nucleotide order in entire genomes or specific regions of DNA or RNA. The application of pharmacogenomics includes neurological diseases, infectious diseases, oncology, cardiovascular diseases, pain management, and other applications. The end-users included hospitals and clinics, research institutions, academic institutes, and others.

What Is The Pharmacogenomics Market Growth Forecast?

The pharmacogenomics market size is expected to see rapid growth in the next few years. It will grow to $15.98 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing investments in precision medicine programs, rising adoption of AI-driven genomic analysis, expansion of pharmacogenomics in oncology and cardiology, growing focus on individualized drug development, continuous advancements in bioinformatics platforms. Major trends in the forecast period include increasing adoption of personalized medicine approaches, rising use of genetic testing in drug selection, growing integration of pharmacogenomic data in clinical workflows, expansion of companion diagnostics, enhanced focus on precision therapeutics.

Global Pharmacogenomics Market Segmentation

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies 2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications 3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users Subsegments: 1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing 2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR 3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis 4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry) 5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays 6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

What Is The Driver Of The Pharmacogenomics Market?

The increasing number of chronic diseases is expected to propel the growth of the pharmacogenomics market going forward. Chronic diseases are medical conditions that persist over an extended period, often for a person's lifetime. The rise in chronic diseases is due to the increasing average lifespan of the global population and the widespread adoption of behavioral risk factors such as sedentary lifestyles, poor diet, and tobacco use. Pharmacogenomics offers a personalized approach to the treatment of chronic diseases, taking into account individual genetic variations that impact drug response. For instance, in 2025, according to the International Diabetes Federation, a Belgium-based health organization, in 2024, around 589 million adults aged 20-79 were living with diabetes, with the total number projected to reach 853 million by 2050 and with more than 4 in 5 adults with diabetes residing in low and middle income countries. Therefore, the increasing number of chronic diseases is driving the growth of the pharmacogenomics industry.

Key Players In The Global Pharmacogenomics Market

Major companies operating in the pharmacogenomics market are Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Genomika Diagnósticos

Global Pharmacogenomics Market Trends and Insights

Major companies operating in the pharmacogenomics market are increasingly focusing on artificial intelligence (AI) driven models that manage drug-drug interactions (DDIs) at the genomic level, thereby improving medication safety, reducing adverse reactions, and enabling highly personalized prescribing. AI-powered pharmacogenetics engines refer to advanced digital systems that use artificial intelligence to analyze a person’s genetic profile and predict how they will respond to specific medications. For example, in December 2024, PGxAI, a US-based artificial intelligence (AI) driven pharmacogenetics company, launched its Sirius model, an AI-powered pharmacogenetics engine that personalizes drug selection, dosage, and drug-drug interaction management based on an individual’s genome. Sirius covers 730 drugs and 40 key pharmacogenes, enabling much broader coverage than traditional pharmacogenomic solutions. The model is designed to be used by hospital systems, diagnostic labs, and clinical research organizations, helping to reduce adverse reactions and improve therapeutic outcomes.

What Are Latest Mergers And Acquisitions In The Pharmacogenomics Market?

In June 2023, Genomenon, a US-based genomics intelligence company, acquired Boston Genetics for an undisclosed amount. The acquisition aims to combine Genomenon's AI-powered genomic platform with Boston Genetics' team of genetic scientists to curate the entire human genome. This acquisition will support clinical diagnostic and pharmaceutical drug development programs by providing valuable insights into the genomic drivers of genetic diseases and oncology. The acquisition also creates a genomics data service arm for Genomenon, allowing the company to provide cost-effective variant curation team extensions for genetic testing labs to speed up their turnaround times. Boston Genetics is a US-based genomics interpretation and curation company.

Regional Outlook

North America was the largest region in the pharmacogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Pharmacogenomics Market?

The pharmacogenomics market includes revenues earned by entities by providing PennCNV, QuantiSNP, GenoCN, and Nexus. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.